Making crime pay: Alkermes aims to treat prison overcrowding
This article was originally published in Scrip
Executive Summary
Alkermes' CEO Richard Pops says he feels a "certain inevitability" over the success of its addiction drug Vivitrol (naltrexone extended-release), despite the fact that sales have been slow. In the US, reveals Mr Pops, Vivitrol is receiving "more and more interest from the criminal justice system including drug courts and state authorities".